Abstract
Metastatic cancers are characterized by uncontrolled cell proliferation and tissue invasion, processes controlled by small Rho GTPases, the activation of which is regulated by GEF and GAP proteins. Deleted in liver cancer (DLC) proteins are such Rho regulators that are downregulated in different types of cancer. Using proteomic approaches, genetically encoded biosensors and high resolution microscopy, our lab studies how the DLC proteins control cellular Rho activity patterns in time and space.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Literatur
Jaffe AB, Hall A (2005) Rho GTPases: biochemistry and biology. Annu Rev Cell Dev Biol 21:247–269
Xue W, Krasnitz A, Lucito R et al. (2008) DLC1 is a chromosome 8p tumor suppressor whose loss promotes hepatocellular carcinoma. Genes Dev 22:1439–1444
Braun AC, Olayioye MA (2015) Rho regulation: DLC proteins in space and time. Cell Signal 27:1643–1651
Yuan BZ, Miller MJ, Keck Cl et al. (1998) Cloning, characterization, and chromosomal localization of a gene frequently deleted in human liver cancer (DLC-1) homologous to rat RhoGAP. Cancer Res 58:2196–2199
Goodison S, Yuan J, Sloan D et al. (2005) The RhoGAP protein DLC-1 functions as a metastasis suppressor in breast cancer cells. Cancer Res 65:6042–6053
Holeiter G, Heering J, Erlmann P et al. (2008) Deleted in liver cancer 1 controls cell migration through a Dia1-dependent signaling pathway. Cancer Res 68:8743–8751
Braun AC, Hendrick J, Eisler SA et al. (2015) The Rho-specific GAP protein DLC3 coordinates endocytic membrane trafficking. J Cell Sci 128:1386–1399
Holeiter G, Bischoff A, Braun AC et al. (2012) The RhoGAP protein Deleted in Liver Cancer 3 (DLC3) is essential for adherens junctions integrity. Oncogenesis 1:e13
Erlmann P, Schmid S, Horenkamp FA et al. (2009) DLC1 activation requires lipid interaction through a polybasic region preceding the RhoGAP domain. Mol Biol Cell 20:4400–4411
Scholz RP, Regner J, Theil A et al. (2009) DLC1 interacts with 14-3-3 proteins to inhibit RhoGAP activity and block nucleocytoplasmic shuttling. J Cell Sci 122:92–102
Author information
Authors and Affiliations
Corresponding author
Additional information
Bettina Noll Jahrgang 1983. 2003–2010 Studium der Technischen Biologie und 2010–2013 Promotion an der Universität Stuttgart. Dort seit 2013 Postdoc am Lehrstuhl für Molekulare Tumorzellbiologie.
Janina Hendrick Jahrgang 1988. 2007–2012 Life science-Studium an der Universität Konstanz. Seit 2013 Promotion am Lehrstuhl für Molekulare Tumorzellbiologie der Universität Stuttgart.
Monilola Olayioye Jahrgang 1972. 1991–1996 Biotechnologiestudium an der TU Braunschweig. 1997–2000 Promotion am Friedrich-Miescher-Institut in Basel, Schweiz. 2000–2003 Postdoc als EMBO-Stipendiatin am Walter and Eliza Hall Institute of Medical Research, Mel - bourne, Australien. 2005–2010 DFG-Nachwuchsgruppenleiterin und seit 2011 DFGHeisenberg- Professorin in Molekularer Tumorzellbiologie an der Universität Stuttgart.
Rights and permissions
About this article
Cite this article
Noll, B., Hendrick, J. & Olayioye, M.A. Rho-Signalgebung in der Tumorentstehung und -progression. Biospektrum 22, 369–372 (2016). https://doi.org/10.1007/s12268-016-0700-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12268-016-0700-5